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Abstract
The desmosomal cadherin desmoglein-1 (DSG1) is an essential intercellular adhesion molecule 
that is altered in various human cutaneous disorders; however, its regulation and function in 
allergic disease remains unexplored. Herein, we demonstrate a specific reduction in DSG1 in 
esophageal biopsies from patients with eosinophilic esophagitis (EoE), an emerging allergic 
disorder characterized by chronic inflammation within the esophageal mucosa. Further, we show 
that DSG1 gene silencing weakens esophageal epithelial integrity, and induces cell separation and 
impaired barrier function (IBF) despite high levels of desmoglein-3 (DSG3). Moreover, DSG1 
deficiency induces transcriptional changes that partially overlap with the transcriptome of 
inflamed esophageal mucosa; notably, periostin, a multipotent pro-inflammatory extracellular 
matrix molecule, is the top induced overlapping gene. We further demonstrate that IBF is a 
pathological feature in EoE, which can be partially induced through the downregulation of DSG1 
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by interleukin-13 (IL-13). Taken together, these data identify a functional role for DSG1 and its 
dysregulation by IL-13 in the pathophysiology of EoE and suggest that the loss of DSG1 may 
potentiate allergic inflammation through the induction of pro-inflammatory mediators such as 
periostin.
Introduction
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease that has emerged over that 
last decade on a worldwide scale1. Although symptomatically resembling gastroesophageal 
reflux disease (GERD), EoE is characterized by immune sensitization to a variety of foods 
and marked Th2-associated allergic inflammation in the esophageal mucosa that is largely 
refractory to acid-suppressive therapy2. During active disease, the histopathological changes 
within the inflamed esophageal mucosa include the dense accumulation of activated immune 
cells, including eosinophils, mast cells, and T and B lymphocytes3. Moreover, evidence of 
dilated intercellular spaces (DIS) and abnormal epithelial cell proliferation suggest that 
impaired barrier function (IBF) of the esophageal epithelium may potentially contribute to 
the pathophysiology of EoE4–6. While dietary modification (i.e., complete or targeted food 
antigen avoidance) and swallowed glucocorticoids alleviate much of the disease pathology, 
EoE still has one of the lowest quality-of-life indexes among other chronic pediatric 
diseases, including inflammatory bowel disease7–9.
Early efforts aimed at the molecular dissection of EoE pathogenesis included gene 
expression profiling of esophageal mucosal biopsies from patients with active EoE, which 
identified a striking disease-associated transcript signature that was highly conserved across 
patients with EoE and largely normalized during glucocorticoid-induced disease 
remission10, 11. Several pro-inflammatory mediators, such as the chemokine (C-C-motif) 
ligand 26 (CCL26), periostin (POSTN), and tumor necrosis factor, alpha-induced protein 6 
(TNFAIP6), were dramatically elevated in the inflamed esophageal mucosa in EoE10 and in 
primary esophageal epithelial cells treated with the Th2 cytokine interleukin-13 (IL-13)11. A 
marked reduction in genes involved in epithelial homeostasis was also observed. In 
particular, the desmosomal cadherin desmoglein-1 (DSG1) exhibited an approximate 8-fold 
decrease in patients with active EoE, which only partially normalized upon disease 
remission11.
DSG1 is a intercellular adhesion molecule belonging to the desmosomal cadherin family, 
which includes desmogleins (DSG1-4) and desmocollins (DSC1-3)12. Desmogleins and 
desmocollins are involved in maintaining epithelial homeostasis where they display spatially 
distinct expression patterns at various levels among different stratified epithelia12, 13. In 
particular, DSG1 is highly expressed in the epidermis and localized primarily within the 
suprabasal epithelial layers, where it regulates cell adhesion and supports epithelial cell 
differentiation14. In contrast, DSG3 is localized to undifferentiated, basal epithelial cells and 
has been suggested to promote cell proliferation15–17.
While the function of DSG1 has been well characterized in the epidermis, its role in the 
esophageal epithelium under both homeostatic and inflammatory conditions remains largely 
unknown. DSG1 mediates intercellular adhesion by forming calcium-dependent heterotypic 
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and homotypic interactions between adjacent epithelial cells via its amino-terminal 
ectodomain18. However, it is becoming increasingly appreciated that DSG1 has additional 
roles beyond that of cell adhesion19. Indeed, DSG1 promotes epithelial differentiation 
through negatively regulating the activation of extracellular signal-regulated kinase (ERK) 
by epidermal growth factor receptor (EGFR) signaling14. DSG1 can also promote epithelial 
differentiation through its interactions with ERBIN, which sequesters SHOC2 to attenuate 
RAS-mediated ERK activation20.
In the present study, we sought to determine the functional consequences of DSG1 
dysregulation in EoE pathogenesis as DSG1 was one of the most down-regulated genes in 
the esophageal mucosa of EoE patients11. We hypothesized that the downregulation of 
DSG1 contributes to the pathological features of the esophageal epithelium in EoE. We 
demonstrate a marked reduction in the gene and protein levels of DSG1 but not DSG3 in the 
esophageal mucosa of patients with EoE. Suppression of DSG1 by shRNA or IL-13 
treatment induced IBF in differentiated esophageal epithelial cells grown at the air-liquid 
interface (ALI); notably, IBF was also observed ex vivo in biopsy samples from patients 
with EoE. Lastly, knockdown of DSG1 was sufficient to induce a gene expression profile, 
which included periostin as the top induced gene, that substantially overlaps with the 
transcriptome of the inflamed esophageal mucosa of patients with EoE. These data suggest 
that the negative regulation of DSG1 by IL-13 can exacerbate inflammation of the 
esophageal mucosa in EoE by enhancing IBF and initiating a pro-inflammatory gene 
expression cascade.
Results
Specific dysregulation of DSG1 in EoE
We sought to establish the relative levels of all desmoglein genes (DSG1-4) in the 
esophagus and to determine whether the downregulation of DSG1 was specific among other 
DSG family members. Whole-transcriptome RNA sequencing of esophageal biopsies from 
healthy controls (NL) (n = 6) and patients with active EoE (n = 10) showed a specific and 
dramatic downregulation of DSG1 in this cohort of patients (Fig. 1A). Indeed, DSG1 
exhibited a 12.7 fold reduction in patients with active EoE (FPKM [median + interquartile 
range] = 19.6 + (4.6 – 24.4) in NL and 0.70 + (0.5 – 1.2) in EoE; p = 1 × 10−3). Notably, the 
most abundant DSG expressed in the esophageal mucosa was DSG3, which did not display 
differential expression in EoE (FPKM [median + interquartile range] = 254.4 + (239.0 – 
279.5) in NL and 258.2 + (218.6 – 326.1) in EoE; p = 0.75) (Fig. 1C). We examined the 
downregulation of DSG1 in a larger cohort of NL and patients with active EoE disease (n = 
25 and 39, respectively) by quantitative PCR (qPCR) and detected a 22.1-fold reduction (p = 
1 × 10−4) in the esophageal expression of DSG1 in active EoE (Fig. 1D). Lastly, we assessed 
esophageal DSG1 levels in patients with inactive EoE (n = 10) following swallowed 
glucocorticoid therapy (Fig. 1E). During disease remission, expression of DSG1 normalized 
to similar levels that were observed in NL (n = 11) yet was significantly different than in 
patients with active disease (n = 13) (p = 3 × 10−4).
We next performed immunofluorescent and/or immunohistochemical staining for DSG1, 
DSG3 and E-cadherin in the esophageal mucosa of NL and patients with active EoE to 
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characterize protein expression and localization. Consistent with previous reports21, 
expression of DSG1 localized to the cell surface and was restricted to the suprabasal 
esophageal epithelium in NL, while DSG1 staining was remarkably absent in patients with 
active EoE (Fig. 2A, upper panel). Conversely, DSG3 was abundantly expressed throughout 
most of the esophageal epithelium in both NL and EoE, with more concentrated staining 
within the basal epithelial cell layers (Fig. 2A, lower panel). Immunohistochemical staining 
for DSG1 revealed a similar downregulation in EoE whereas expression of E-cadherin, a 
ubiquitously expressed cadherin molecule that regulates epithelial homeostasis and barrier 
formation22, was unchanged between NL and patients with active EoE (Fig. 2B); these 
findings were supported at the gene level by qPCR analysis of esophageal biopsies from NL 
and active EoE patients (data not shown). These cumulative data indicate a specific 
downregulation of the DSG1 gene and protein in EoE, and that this is unique from the 
expression patterns of other desmogleins and E-cadherin.
Loss of DSG1 regulates esophageal epithelial cell integrity in vitro
In order to investigate the functional consequences of DSG1 dysregulation on the 
esophageal epithelium, we developed a modified ALI culture system to induce a stratified 
esophageal epithelium in vitro. Similar ALI models have been used to study differentiated 
epithelium of both the epidermis and esophagus23, 24. Confluent monolayers of 
immortalized esophageal epithelial cells (EPC2), which have been previously shown to form 
stratified esophageal epithelium25–27, were exposed to the ALI in the presence of high Ca2+ 
(1.8 mM). Following 5–7 days of differentiation at the ALI, the EPC2 cells formed a 
stratified epithelium as indicated by the differential H&E staining when compared to 
submerged cells (Fig. 3A). Gene expression analyses after ALI exposure showed significant 
induction of DSG1 and keratin 10 (KRT10) (411 fold, p < 1 × 10−3 and 6,240 fold, p < 1 × 
10−2, respectively), both of which are expressed specifically in differentiated esophageal 
epithelial cells21, 28, 29 (Fig. 3B–C).
We next utilized lentiviral shRNA gene silencing to directly examine the impact of DSG1 
dysregulation on esophageal epithelial cell adhesion. EPC2 cells that were stably transduced 
with a DSG1 shRNA exhibited a 92% reduction in DSG1 expression compared to cells 
transduced with a non-silencing control (NSC) shRNA (p < 5 × 10−3) (Fig. 4A), whereas 
DSG3 levels remained unaffected (Fig. 4B). Histological analyses of the NSC shRNA-
transduced cells grown at the ALI showed normal stratification with a differentiated, intact 
esophageal epithelium (Fig. 4C, upper panel). However, while the differentiation appeared 
normal in the DSG1 shRNA-transduced cells, prominent cellular separation was evident in 
the suprabasal layers (arrows, Fig. 4C, lower panel). Importantly, this cellular separation 
was consistently observed only in the DSG1-deficient cells (and not the NSC controls cells) 
using multiple DSG1 shRNA clones, indicating that the observed phenotype was not due to 
sample sectioning (data not shown). A similar phenotype was observed when ALI-
differentiated EPC2 cells were treated directly with recombinant wild type (WT) exfoliative 
toxin A (ETA), a DSG1-specific protease produced by S. aureus and the causative agent of 
epidermal blistering in staphylococcal scalded-skin syndrome (SSSS)30 (Fig. 4D, lower 
panel). Notably, the inactive mutant form of ETA (S195A) did not induce cellular separation 
(Fig. 4D, upper panel). To directly measure whether loss of DSG1 reduced esophageal 
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epithelial cell adhesion, NSC or DSG1 shRNA-transduced cells were subjected to a dispase 
adhesion assay. Following mechanical disruption, a significantly greater amount of cell 
dissociation was observed in cells deficient in DSG1 than in control cells (p < 5 × 10−2) 
(Fig. 4E–F).
IBF in EoE and in DSG1-deficient esophageal epithelial cells in vitro
To assess the integrity of the esophageal epithelium in EoE at the ultra-structural level, we 
performed electron microscopy on NL and EoE patient biopsies. While the esophageal 
epithelium of NL patients was composed of cohesive, intact epithelia, prominent DIS were 
evident throughout the esophageal epithelium of patients with EoE (arrowheads, Fig. 5A). 
These findings, which have been noted in previous studies of both EoE and GERD31, 32, 
were consistent across multiple sections from the same patient and among different patients. 
We next assessed whether IBF is indeed a pathological defect in EoE by measuring 
transepithelial electrical resistance (TER) ex vivo in esophageal biopsies from NL and 
patients with EoE (Fig. 5B). We found that transcellular permeability was reduced by 
approximately 62% in patients with EoE compared to in NL (RT = 84 ± 28 vs. 224 ± 23 
ohms × cm2, respectively; p < 5 × 10−3). We also analyzed paracellular permeability in EoE 
by measuring macromolecular flux in esophageal biopsies and observed an approximate 46-
fold increase in those from patients with EoE compared to NL (p < 5 × 10−2). Notably, 
esophageal expression of occludin (OCLN) and genes in the claudin (CLDN) and tight 
junction protein (TJP) families was not reduced in EoE, suggesting the IBF in EoE occurs in 
the absence of marked alteration to tight junctions (Supplementary Fig. 1A–C).
We hypothesized that the cellular separation that occurs within the esophageal epithelium 
following the loss of DSG1 (Fig. 4C) may contribute to the IBF observed in EoE (Fig. 5A–
C). To test this possibility, we measured TER and paracellular permeability in the ALI-
differentiated NSC or DSG1 shRNA-transduced EPC2 cells. Reduced DSG1 expression 
resulted in impaired TER (p < 5 × 10−3, Fig. 5D) and increased FITC-dextran flux (p < 5 × 
10−2, Fig. 5E–F) by approximately 42% and 33%, respectively. These data identify a novel 
mechanism whereby loss of DSG1 negatively affects esophageal epithelial integrity and is 
sufficient to induce IBF.
IL-13 regulates DSG1 and promotes IBF in differentiated esophageal epithelial cells
IL-13 is a critical Th2 cytokine capable of eliciting some of the transcriptional changes 
within the inflamed esophageal epithelium that are associated with EoE, including the 
downregulation of multiple epithelial cell differentiation genes11, 33. Therefore, we assessed 
the effects of IL-13 on the integrity and barrier formation of ALI-differentiated esophageal 
epithelial cells. Esophageal epithelial cells were left untreated or treated with 10 or 100 
ng/mL IL-13 continuously throughout the ALI differentiation process. Both concentrations 
of IL-13 induced partial cellular separation within the suprabasal epithelial layers (arrows, 
Fig. 6A, middle and lower panels).
As the IL-13-induced suprabasal cell separation partially reflected the phenotype of DSG1-
deficient cells (Fig. 4C), we next investigated the ability of IL-13 to regulate DSG1 
expression. IL-13 treatment suppressed the induction of DSG1 in ALI-differentiated 
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esophageal epithelial cells (Fig. 6B), whereas induction of KRT10 (Fig. 6C) and DSG3 (data 
not shown) were unaffected. Importantly, IL-13 also promoted IBF, as a significant 
reduction in TER was observed at both 3 and 5 days post treatment with IL-13 (100 ng/mL) 
compared to untreated cells (Fig. 6D).
We also tested whether IL-13 could attenuate DSG1 expression in vivo using a transgenic 
murine model of EoE. Doxycycline (Dox)-inducible expression of IL-13 in the lung (using 
the Clara cell-specific promoter CC10) has been shown to induce an EoE phenotype in 
mice34. Elevated IL-13 levels in the BAL and induced esophageal eosinophilia were 
detected in the Dox-treated animals (Supplementary Fig. 1A–B). Overexpression of IL-13 in 
treated (+ Dox) mice reduced DSG1 mRNA and protein levels in the esophageal mucosa as 
compared to untreated (-Dox) mice (Supplementary Fig. 1C–E).
Loss of DSG1 primes for the innate inflammatory transcript signature
DSG1 has been shown to counter-regulate EGFR signaling, and more recently RAS-
mediated signaling, through mechanisms that are independent of its full-length, adhesive N-
terminal domain14, 20. Therefore, we hypothesized that DSG1 deficiency may also regulate 
downstream signaling responses associated with the Th2 inflammation in EoE. To test this 
possibility, we performed microarray analyses on NSC and DSG1 shRNA-transduced EPC2 
cells following ALI-differentiation. Interestingly, 63 transcripts coding for 53 unique genes 
were differentially expressed in the DSG1-deficient cells compared to in control cells (p < 5 
× 10−2, fold change > 2.0) (Fig. 7A). Notably, there was a substantial overlap between this 
transcript profile and the EoE transcriptome identified in patient esophageal biopsies by 
RNA sequencing (RNA-seq); 60% of the unique DSG1-regulated transcripts were also 
dysregulated in esophageal biopsies of patients with EoE (Fig. 7B and Supplementary Table 
1). In particular, periostin (POSTN) was the most highly induced gene upon DSG1 
knockdown in esophageal epithelial cells (2.5 fold) and was dramatically elevated in 
esophageal tissue of patients with EoE (384 fold) (Supplementary Table 1).
We next validated the significant increase in POSTN levels in DSG1-deficient esophageal 
epithelial cells by qPCR and observed a 17-fold increase in POSTN in the DSG1 versus NSC 
shRNA-transduced cells (p < 5 × 10−2) (Fig. 8A). Furthermore, qPCR analysis demonstrated 
a significant and dramatic increase in POSTN expression in the esophageal mucosa of 
patients with active EoE compared to NL (p < 1 × 10−4, fold change = 2,047) (Fig. 8B). 
Notably, POSTN levels in EoE showed a significant inverse correlation with DSG1 
expression (same cohort as in Fig. 1D) (Spearman r = −0.33, p = 0.02) (Fig. 8C). Together, 
these data indicate that IL-13-induced loss of DSG1 augments the allergic inflammatory 
response by promoting IBF and likely elevates pro-inflammatory gene expression in EoE 
(Fig. 9).
Discussion
The data presented herein characterize the pathological impact of DSG1 dysregulation in 
EoE and define a non-redundant role for DSG1 in the regulation of the esophageal epithelial 
barrier function and homeostasis. In particular, we demonstrated a specific and marked 
downregulation of DSG1 in the esophageal epithelium of patients with EoE that was largely 
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reversible with patient disease status. This loss in DSG1 expression was sufficient to induce 
cell separation and IBF in the esophageal epithelium. Moreover, DSG1 deficiency led to an 
esophageal epithelial transcript signature that included increased gene expression of the pro-
inflammatory extracellular matrix molecule periostin. These findings are particularly notable 
in view of the relatively high abundance of DSG3 expression in EoE and in our in vitro 
model, demonstrating the lack of redundancy for DSG1’s regulation of esophageal 
responses, particularly during allergic inflammation. Interestingly, in GERD, in which DIS 
and IBF have been attributed to acid exposure of the esophageal epithelium, esophageal 
expression of DSG1 (and DSG3 to a lesser extent) is increased35, further suggesting a 
unique, non-redundant and essential role for DSG1 in regulating disease processes 
specifically linked with EoE pathology.
Our data identify IL-13 as a potent regulator of DSG1 expression in human esophageal 
epithelial cells cultured at the ALI and in mouse esophageal epithelial cells in a murine 
model of EoE. This latter finding is quite striking given the physiological differences 
between the human and mouse esophagus (not keratinized versus keratinized, respectively) 
and the existence of multiple murine Dsg1 isoforms (α, β, and γ)36, which were universally 
detected in our qPCR analysis and immunofluorescent staining (see Supplementary 
Materials and Methods). Previous work has demonstrated a pronounced effect of IL-13 on 
global gene expression in primary esophageal epithelial cells, and in particular, genes 
involved in epithelial differentiation11, 33. DSG1 was not shown to be regulated by IL-13 in 
these data, which, on the basis of our data in the ALI system (Fig. 3), we hypothesize was 
due to the low levels of DSG1 expression in esophageal epithelial cells grown in the 
submerged culture conditions used in these studies. Interestingly, in skin keratinocytes, 
which express high baseline levels of DSG1 even in submerged cultures, IL-4 has been 
shown to downregulate DSG1 expression in vitro37. Notably, both IL-13 and IL-4 are 
significantly increased in the peripheral blood and esophageal mucosa of patients with active 
EoE38, 39 and preliminary data indicate that IL-4 is also capable of negatively regulating 
DSG1 expression and inducing IBF in ALI-differentiated esophageal epithelial cells in vitro 
(data not shown). These data, together with our findings that esophageal expression of DSG1 
normalizes in EoE patients during disease remission, indicate DSG1 is negatively regulated 
by Th2 cytokines during allergic inflammation.
Within the epithelial barrier of the epidermis and intestine, the selective ability to 
discriminate the uptake of molecules based on size and charge is attributed to the tight 
junction complex40. For example, several tight junction genes are expressed within the 
epidermis including CLDN1, CLDN4, TJP1, and OCLN41. While only CLDN1 has been 
demonstrated to have an essential role in epidermal barrier function in vivo42, a recent study 
has shown CLDN4, TJP1, and OCLN can also independently regulate epidermal 
permeability in vitro43. Although the esophageal epithelial barrier has been studied primarily 
in the context of GERD, tight junction proteins have been shown to have no correlation with 
GERD pathogenesis44. Moreover, our data (Supplementary Fig. 1) demonstrate no decrease 
in genes encoding claudins, tight junction proteins, or occludin in EoE; none of these genes 
were dramatically altered in DSG1-deficient cells following shRNA transduction or IL-13 
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treatment (Supplementary Table 3). Together, these data suggest physiologically distinct 
mechanisms regulate the epithelial barrier properties of the esophagus and the epidermis.
Despite our evidence substantiating IBF as a bona fide pathological feature in EoE, little is 
known regarding the role of the esophageal barrier in regulating allergic inflammation. 
Within the epidermis, Langerhans cells continually sample external antigens by inducing 
transient reorganization of tight junctions within the stratum corneum without affecting 
barrier integrity; this homeostatic surveillance is further amplified in activated Langerhans 
cells45. These data suggest a potential mechanism by which IBF could lead to increased 
antigen sensitization, which is dependent on tissue resident antigen presenting cells. It is 
important to note that Langerhans cells46, 47 and high baseline expression of the high affinity 
IgE receptor FcεRI48 have been observed in both healthy and inflamed esophageal 
epithelium. Moreover, data suggesting esophageal epithelial cells can present antigen and 
MHC class II expression is increased in EoE49 further suggest that the esophagus is not a 
unifunctional, static organ involved solely in food transport, but rather has an active role in 
immunosurveillance during allergic inflammation.
Our finding of elevated periostin expression in DSG1-deficient cells is particularly notable 
as periostin has been implicated in multiple allergic inflammatory disease including asthma, 
atopic dermatitis, and EoE50–52. Periostin can directly enhance eosinophil adhesion50, 53, as 
well as increase keratinocyte production of thymic stromal lymphopoetin (TSLP)52, a potent 
Th2-skewing cytokine that has been genetically linked to EoE susceptibility54, 55. Although 
periostin is expressed primarily in fibroblasts, treatment of both bronchial epithelial cells56 
and esophageal epithelial cells50 with IL-13 induces periostin expression in these cell types. 
Interestingly, periostin has been shown to enhance signaling through EGFR and integrin 
αvβ5 to induce epithelial-mesenchymal transition (EMT)57, a process associated with the 
loss of epithelial cell markers as epithelial cells adopt a fibroblast-like phenotype and 
increased migratory properties (e.g., loss of cell adhesion)58. While a previous report 
demonstrated that DSG1 supports epithelial differentiation and reduces proliferative 
capacity through negative regulation of EGFR signaling14, a similar suppressive effect of 
DSG1 on EMT induction has not been addressed. As it has been recently proposed that 
EMT is actively occurring in EoE59, 60, perhaps the loss of DSG1-dependent adhesion and 
the upregulation of periostin synergistically disrupt the homeostatic interactions between 
epithelial cells and fibroblasts during allergic inflammation.
The clinical importance of DSG1 and its role in maintaining epithelial integrity has been 
reported in several cutaneous diseases of autoimmune, infectious, and genetic origin30. In 
pemphigus foliaceous, autoantibodies against the ectodomain of DSG1 induce severe 
epidermal acantholysis30; interestingly, heightened Th2 inflammation, including elevated 
Th2 cytokine expression61 and the presence of activated eosinophilic infiltrates62, are 
observed in some instances. In Netherton syndrome, an epidermal inflammatory disease 
involving IBF with marked eosinophilia and elevated IgE levels63, the primary etiology has 
been attributed to the genetic loss of the epithelial-derived serine protease inhibitor, Kazal 
type, 5 (SPINK5)64. In this disease, the uncontrolled activity of endogenous trypsin-like 
proteases leads to aberrant cleavage of epithelial barrier proteins within the stratum corneum 
(including DSG1). Mice deficient in Spink5 display increased DSG1 degradation and 
Sherrill et al. Page 8













significant epidermal pathology, including epidermal acantholysis and IBF65. However, it 
has been unclear whether the loss of DSG1 alone is sufficient to induce IBF as several 
proteases (e.g., kallikriens 5, 7, and 14 and elastase 2) and stratum corneum proteins are 
involved in barrier formation (e.g., filaggrin, involucrin, and loricrin) and are also altered in 
Netherton syndrome65–67.
Recently, genetic variants in DSG1 were identified in a new clinical syndrome manifesting 
with severe atopic dermatitis, multiple allergies, and metabolic wasting (SAM syndrome) in 
two consanguineous families68. Homozygous loss-of-function variants led to reduced 
expression of DSG1 and loss of cell adhesion68. Notably, one of three patients with SAM 
syndrome was reported to have EoE as well as elevated keratinocyte expression of IL5 and 
TSLP68. Interestingly, in a genome-wide association study, we identified a non-coding 
variant in intron 1 of DSG1 with suggestive association with EoE risk (meta p = 6.57 × 
10−6)54, the function of which has yet to be determined. Nonetheless, these supportive 
findings in SAM coincide with our data as they provide additional evidence that links DSG1 
deficiency as an initiating factor to IBF in allergic inflammation.
In summary, the observations presented herein support a pathophysiological role for DSG1 
dysregulation in EoE. We propose a pathogenic cycle in which the localized increase in 
select Th2 cytokines (e.g. IL-13) within the inflamed esophagus decreases expression of 
DSG1, which is sufficient to weaken esophageal epithelial integrity and induce IBF. This 
loss of DSG1 initiates a pro-allergic transcriptional response (e.g., increased periostin 
expression) that potentiates the inflammatory response and may have far-reaching 
implications beyond the initial IBF insult, such as promoting EMT (Fig. 9).
Methods
Human subjects
NL (healthy control patients) were defined as having no history of EoE diagnosis with 0 
eosinophils per high-power field (HPF) and no evidence of esophagitis within distal 
esophageal biopsies obtained during the same endoscopy procedure as the analyzed samples. 
Patients with EoE had clinician-diagnosed EoE and as having active disease in concomitant 
distal esophageal biopsies with greater than 15 eosinophils per HPF. EoE patients in disease 
remission (inactive) had clinician-diagnosed EoE and distal esophageal biopsies with less 
than 15 eosinophils per HPF (range = 0–1) following swallowed glucocorticoid therapy.
RNA sequencing (RNA-seq) and bioinformatic analyses
RNA isolated from esophageal biopsies of 6 NL and 10 patients with active EoE (mean 
eosinophils/HPF = 164 ± 29 SEM) was subjected to RNA sequencing at the CCHMC Gene 
Discovery and Genetic Variation Core as previously described69. The paired-end sequencing 
reads were aligned against the GRCh37 genome model using TopHat 2.04 with Bowtie 
2.0370, 71. The separate alignments were then merged using Cuffmerge with RefSeq gene 
models as a reference. The aligned reads were then quantified for differential expression 
analysis using Cuffdiff72. Statistical significance was determined using a t-test with a 
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threshold of p < 5 × 10−2 and a 2.0-fold cut-off filter in GeneSpringR 11.5 (Agilent 
Technologies Incorporated, Clara, CA, USA).
qPCR analysis
RNA samples were prepared as previously described34. Briefly, total RNA (250–500 ng) 
was DNAase treated, and cDNA was generated using the iScriptTM cDNA synthesis kit 
(Bio-Rad Laboratories, Hercules, CA, USA). qPCR was performed, and SYBRR Green 
incorporation was analyzed using iQ5 software (Bio-Rad Laboratories, Hercules, CA, USA). 
Specific primer sequences are listed in Supplementary Table 2.
Immunohistochemical and immunofluorescent staining. For immunohistochemical staining, 
formalin-fixed, paraffin-embedded distal esophageal biopsies were serially sectioned and 
de-paraffinized using xylene followed by graded ethanol washes. Heat-induced epitope 
retrieval in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, p.H. 6.0) was 
used, and endogenous peroxidase activity was quenched in 2% H2O2. Slides were blocked 
in PBS with 3% goat serum for 1 hr followed by overnight incubation at 4°C in the 
following primary antibodies (2 μg/mL): anti-DSG1 (sc-2011) (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) or anti-E-cadherin (#3195, Cell Signaling Technology, Inc., Danvers, 
MA, USA). Slides were then washed, incubated for 1 hr at room temperature in biotin-
conjugated anti-rabbit IgG (1:250), and developed using the Vectastain ABC System 
according to manufacturer’s protocol (Vector Laboratories, Burlingame, CA, USA). Lastly, 
developed slides were counterstained with Harris hematoxylin. Immunofluorescent staining 
was performed as previously described50 using the following primary antibodies (2 μg/mL): 
anti-DSG1 (sc-2011) or anti-DSG3 (sc-23912) (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). Nuclei were stained with DAPI. Patients with active EoE that were analyzed by 
staining had eosinophil levels ranging from 98 to 265 eosinophils per HPF.
ALI culture system
The esophageal epithelial cell line (human telomerase reverse transcriptase [hTERT]-
immortalized EPC2 cell line) was a kind gift from Dr. Anil Rustgi (University of 
Pennsylvania, Philadelphia, PA, USA) and has been extensively characterized in previous 
studies25, 26, 73. For the ALI culture system, EPC2 cells were grown to confluence while 
fully submerged in low-calcium ([Ca2+] = 0.09 μM) keratinocyte serum-free media (K-
SFM) (Life Technologies, Grand Island, NY, USA) on 0.4-μm pore-size permeable supports 
(Corning Incorporated, Corning, NY, USA). Confluent monolayers were then switched to 
high-calcium ([Ca2+] = 1.8 μM) K-SFM for an additional 3–5 days. To induce epithelial 
stratification and differentiation, the culture medium was removed from the inner chamber 
of the permeable support in order to expose the cell monolayer to the air interface. 
Differentiated esophageal epithelial equivalents were analyzed 5–7 days post exposure.
DSG1 knockdown
EPC2 cells were transduced with shRNA targeting the last exon of DSG1 or a NSC shRNA 
using the GIPZ lentiviral system (Thermo Fisher Scientific, Rockford, IL, USA). Lentiviral 
particles were prepared at the CCHMC Viral Vector Core facility. Forty-eight hours post 
transduction, cells were selected for stable integration using puromycin (1 μg/mL), which 
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was maintained throughout all subsequent experiments. Transduction efficiency was 
assessed by GFP fluorescence, and knockdown efficiency as compared to NSC shRNA-
transduced cells was assessed by qPCR and immunofluorescence staining as described 
herein.
Expression and purification of recombinant ETA
The plasmids encoding WT ETA or the inactive ETA mutant S195A74 with a 5X histidine 
epitope tag75 were kindly provided by Dr. John Stanley (University of Pennsylvania, 
Philadelphia, PA, USA). The cDNAs were subcloned into the pT7-7 vector, validated by 
Sanger sequencing, and purified from isopropyl β-D-1-thiogalactopyranoside (IPTG)-
induced BL21 (DE3) pLysS E. coli cell lysates using Ni+-NTA agarose column 
chromatography (QIAGEN Incorporated, Germantown, MD, USA). Purified ETA WT and 
S195A proteins were analyzed by SDS-PAGE and Coomassie staining or western blot using 
anti-histidine antibodies; in transiently transfected HEK293T cells, cleavage of DSG1 by 
WT ETA protein and non-cleavage of DSG1 by S195A ETA protein were confirmed by 
western blot (data not shown). Final protein concentrations were determined by 
bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, Rockford, IL, USA).
Dispase adhesion assays
Dispase adhesion assays were performed as previously described76. Briefly, confluent 
monolayers of NSC or DSG1 shRNA-transduced EPC2 cells were grown in 1.8 mM Ca2+ 
for 24 h, washed twice with PBS, and then detached from tissue culture wells by incubation 
in 2.4 U/mL dispase (Life Technologies Corporation, Grand Island, NY, USA) for 15–20 
min at 37°C. Detached monolayers were then subjected to mechanical stress by pipetting 
with a 1-mL pipet 5 times. Aliquots were then cyto-centrifuged and stained with Hema 3R 
(Thermo Fisher Scientific, Rockford, IL, USA). One-, two-, and three-cell clusters were 
counted from the entire field under 10X magnification.
Microarray analyses
RNA was isolated using the miRNeasy kit (QIAGEN Incorporated, Germantown, MD) 
according to the manufacturer’s protocol. RNA quality assessment, library preparation, 
hybridization to the GeneChipR Human Gene 2.0 ST exon array (Affymetrix, Santa Clara, 
CA, USA), and analysis were performed at the CCHMC Gene Expression Microarray Core. 
Expression profiles were analyzed using GeneSpringR 11.5 (Agilent Technologies 
Incorporated, Clara, CA, USA), and statistical significance was determined using a t-test 
with a threshold of p < 5 × 10−2 and a 2.0-fold cut-off filter.
Electron microscopy
Transmission electron microscopy was performed at the Pathology Research Core at 
Cincinnati Children’s Hospital Medical Center (CCHMC). Biopsy specimens used in this 
analysis were from NL (n = 3) and from patients with active EoE (n = 3) who had a previous 
EoE diagnosis and an esophageal biopsy with greater than 15 eosinophils per HPF (range = 
60–100 eosinophils/HPF). The representative images shown were taken at 10,000X 
magnification.
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TER and paracellular flux assays
For ex vivo studies, esophageal biopsies from NL or patients with active EoE were mounted 
into mini-Ussing chambers, and TER measurements and paracellular flux assays using 
FITC-dextran (average molecular weight = 4 kDa) were performed as previously 
described77. A total of 6 NL biopsies were analyzed for TER and paracellular permeability. 
A total of 9 and 4 biopsies from patients with EoE were assessed for TER and paracellular 
permeability, respectively. To account for potential differences in biopsy thickness across 
the different patient groups, an arbitrary cut-off of 2% FITC-dextran flux was used, resulting 
in 5 of the 9 biopsies from patients with EoE being excluded. The data shown represent the 
mean ± SEM. In vitro measurements for TER following IL-13 treatment were assessed 
using an EVOM (World Precision Instruments, Inc., Sarasota, FL, USA), whereas TER and 
paracellular flux assays in DSG1-deficient cells were performed as previously described78.
Statistical analyses
Statistical significance was determined using a t-test (two-tailed). Non-normally distributed 
data from patient biopsy samples were analyzed using a Mann-Whitney test, and the 
Spearman correlation was used to test for correlated gene expression. All statistical analyses 
were performed using GraphPad PrismR (GraphPad Software Incorporated, La Jolla, CA, 
USA).
Study approvals
For human subjects, written informed consent was obtained prior to a patient’s enrollment in 
the studies, and all human studies were approved by the CCHMC Institutional Review 
Board (IRB protocol 2008-0090). All experiments involving mice were approved by the 
CCHMC IACUC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Specific reduction in desmoglein-1 (DSG1) gene expression in EoE
Heatmap depicting expression levels of desmogleins 1–4 (DSG1–4) (A) and individual 
FPKM values for DSG1 and DSG3 (B-C) from RNA sequencing of esophageal biopsies 
from 10 patients with active EoE versus 6 healthy controls (NL). Quantitative PCR (qPCR) 
analysis of DSG1 expression in esophageal biopsies from NL (n = 25) and patients with 
active EoE (n = 39) (D). qPCR analysis of DSG1 expression in esophageal biopsies from NL 
(n = 11) and patients with inactive (n = 10) or active (n = 13) EoE (E). Data are represented 
as the median + interquartile range: NS (not significant), *** p < 5 × 10−4, and **** p < 1 × 
10−4.
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Figure 2. Loss of DSG1 protein expression in EoE
Immunofluorescence (A) or immunohistochemical staining (B) of esophageal biopsy 
sections from controls (NL) and patients with active EoE. In (A), DSG1 (upper panel, in 
red) and DSG3 (lower panel, in green) are shown. Nuclei are stained with DAPI (blue). In 
(B), DSG1 (upper panel, in brown) and E-cadherin (lower panel, in brown) are shown. 
Dashed lines in (A) and (B) indicate the basal epithelial layer. Images in are representative 
of 4 patients per group.
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Figure 3. Differentiation of esophageal epithelial cells at the air-liquid interface (ALI)
H&E-stained sections of EPC2 cells grown in submerged cultures or differentiated at the 
ALI (A). qPCR analysis of desmoglein-1 (DSG1) (B) and keratin 10 (KRT10) (C) 
expression in submerged or ALI-differentiated EPC2 cells. Data are representative of 4 
experiments performed in duplicate and are represented as the mean + SEM: ** p < 5 × 10−3 
and *** p < 5 × 10−4.
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Figure 4. Loss of DSG1 reduces esophageal epithelial cell adhesion
qPCR analysis of DSG1 (A) and DSG3 (B) in ALI-differentiated EPC2 cells stably 
transduced with non-silencing control (NSC) or DSG1 shRNA. H&E-stained sections from 
stably transduced cells differentiated at the ALI (C). H&E-stained sections from EPC2 cells 
exposed to the air interface and treated with 10 μg/mL ETA (WT) or the S195A inactive 
mutant for 24 h (D). Arrows (C–D) indicate cell separation within the suprabasal epithelium. 
Cytospins from NSC or DSG1 shRNA-transduced EPC2 cells following dispase adhesion 
assays (E) and quantification of dissociated cell clusters are shown (F). Images in (C–E) are 
representative of 4–5 experiments performed in duplicate. Data in (A–B) and (E) are from 3 
experiments performed in duplicate and are represented as the mean + SEM: NS (not 
significant), * p < 5 × 10−2 and ** p < 5 × 10−3.
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Figure 5. Impaired barrier function (IBF) in EoE can be replicated in DSG1 deficient esophageal 
epithelial cells
Representative electron micrographs of esophageal biopsies from healthy (NL) controls (n = 
3) and patients with active EoE (n = 3). Arrowheads indicate the presence of dilated 
intercellular spaces (DIS) in EoE (A). TER (RT) measurements from esophageal biopsies 
from healthy (NL) control and patients with active EoE (n = 6 and 9, respectively) (B). 
FITC-dextran flux assays from NL and active EoE esophageal biopsies (n = 6 and 4, 
respectively) (C). TER (RT) measurements from NSC and DSG1 shRNA-transduced EPC2 
cells following ALI differentiation (D). Kinetic analysis of FITC-dextran flux was also 
performed (E). Total FITC-dextran flux following 180 minutes are depicted in (F). Data in 
(D–F) are from two independent experiments performed in quadruplicate. All data are 
represented as the mean + SEM: *, p < 5 × 10−2 ; **, p < 5 × 10−3.
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Figure 6. IL-13 downregulates DSG1 and promotes IBF in esophageal epithelial cells
H&E-stained sections of EPC2 cells differentiated at the ALI in the presence of 0 
(untreated), 10, or 100 ng/mL IL-13 (A). Arrows indicate a cell separation within to the 
suprabasal epithelium. Images are representative of 3 experiments performed in duplicate. 
Expression levels of DSG1 (B) and KRT10 (C) were measured by qPCR in submerged or 
ALI-differentiated EPC2 cells in the absence (0 ng/mL) or presence of IL-13 (10 or 100 ng/
mL). TER (RT) measurements on EPC2 cells at 0, 3, and 5 days following differentiation at 
the ALI in the absence (untreated) or presence of IL-13 (100 ng/mL) (D). Data are from 3 
experiments performed in duplicate and are represented as the mean + SEM: NS (not 
significant), ** p < 5 × 10−3 and *** p < 1 ×10−4 as compared to the untreated cells at the 
same days post-ALI differentiation.
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Figure 7. Loss of DSG1 promotes epithelial pro-inflammatory transcriptional responses
Heatmap of 63 transcripts with differential expression (p < 5 × 10−2, fold change > 2.0) in 
DSG1-deficient EPC2 cells compared to non-silencing control (NSC) cells following ALI-
differentiation (A). Venn diagram depicting the number of genes (n = 32) (boxed transcripts 
in [A]) dysregulated following DSG1 knockdown that overlap with differentially expressed 
genes in esophageal mucosa of EoE patients (n = 10) compared to healthy control patients 
(NL) (n = 6) identified by RNA sequencing (B).
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Figure 8. DSG1 deficiency increases periostin (POSTN) expression
qPCR analysis of POSTN expression in non-silencing control (NSC) and DSG1 shRNA-
transduced EPC2 cells following ALI differentiation (A) and in patient biopsies (same 
cohort as in Fig. 1D) (B). Spearman correlation between esophageal expression of POSTN 
and DSG1 (from Fig. 1D) in patients with active EoE (C). Data in (A) are representative of 
three independent experiments performed in duplicate and represented as the mean + SEM: 
* p < 5 × 10−2 and **** p < 1 × 10−4.
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Figure 9. Model of DSG1 dysregulation in EoE pathogenesis
Downregulation of DSG1 by select Th2 cytokines (e.g. IL-13) results in impaired barrier 
function (IBF) and increased antigen exposure as well as the expression of pro-allergic 
mediators including periostin (POSTN), forming a pathogenic cycle to further exacerbate 
allergic inflammation. Inset shows H&E staining of inflamed esophageal mucosa with 
dilated intercellular spaces (DIS) (arrowheads) and eosinophilic infiltration (arrows).
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